Venture Kick

CellX Biosolutions specializes in sustainable chemical waste management. It offers services such as custom bacterial community biodiscovery and optimization, biodegradability studies, and deployment using microfluidic devices. The company helps industries treat pollutants like PFAS, pharmaceuticals, and microplastics, and enables chemical and pharmaceutical producers to manage their waste cost-effectively and sustainably.

Azure Cell Therapies is a biotech company developing next-gen CGTs for neurodegenerative diseases

Shape Biopharmaceuticals is a biotechnology company that specializes in the development of immunotherapeutic drugs aimed at treating chronic diseases with limited treatment options. The company focuses on advanced protein design and formulation technologies to create a new generation of immunotherapies. By addressing unmet medical needs, Shape Biopharmaceuticals seeks to improve patient outcomes for individuals with genetically driven conditions who lack effective therapeutic alternatives. Through its innovative healthcare solutions, the company aims to provide hope and enhance treatment possibilities for patients facing significant health challenges.

Nerai Bio is a biotechnology company that specializes in advancing genetic therapies. It operates an AI-assisted CRISPR protein engineering platform, enabling clients to enhance the development of next-generation therapeutic systems.

CellX Biosolutions specializes in sustainable chemical waste management. It offers services such as custom bacterial community biodiscovery and optimization, biodegradability studies, and deployment using microfluidic devices. The company helps industries treat pollutants like PFAS, pharmaceuticals, and microplastics, and enables chemical and pharmaceutical producers to manage their waste cost-effectively and sustainably.

Abrinca Genomics is a biotechnology company specializing in the development of a web-based platform for managing and analyzing microbial genomics data. The platform is designed to be self-hosted, scalable, and dataset-independent, allowing researchers and bioinformaticians to securely organize, explore, and analyze vast volumes of microbial genome data. It supports multiple annotation formats, offers flexible access controls, and integrates seamlessly into existing workflows.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.

Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

ASTRA Therapeutics is a medication development company focused on creating innovative therapies for parasitic diseases. Utilizing advanced science and technology, the company develops precision-engineered drugs to combat a wide range of parasitic disorders, including malaria, cryptosporidiosis, and toxoplasmosis. Its mission is to address the global health burden posed by these conditions by bringing effective treatment candidates to market.

Tandem Therapeutics is a biopharmaceutical company dedicated to pioneering treatments for fibrotic diseases. It focuses on the extracellular matrix, a complex network of proteins that surrounds cells, and develops peptide therapeutics, known as Matrix Targeting Peptides (MTPs), to target and treat the extracellular matrix barrier. This innovative approach aims to provide more precise and effective treatments for patients suffering from fibrotic conditions, including cancers and organ fibrosis.

Aukera Therapeutics is a biotechnology company focused on creating innovative therapeutics for patients afflicted by diseases related to the mTOR protein, including cancer and neurodegenerative disorders. Originating as a spin-off from the Biozentrum of the University of Basel, the company has developed a pharmaceutical drug discovery engine aimed at producing selective inhibitors of the mTOR complex. This technology enables the development of drugs that specifically target various branches of the mTOR signaling pathway, which plays a crucial role in regulating cell growth. By providing targeted treatments, Aukera Therapeutics seeks to improve patient outcomes in the management of mTOR-related diseases.

Biosimo Chemicals is a chemical engineering start-up focused on the development and operation of processes to produce bio-based platform chemicals. The company aims to create sustainable chemical solutions through innovative catalytic reactions and purification processes. Its flagship technology offers a novel method for producing acetic acid, replacing traditional methods that rely on coal and gas with a process that utilizes ethanol derived from biomass and waste. This advancement provides the chemical, pharmaceutical, and materials industries with a direct alternative to fossil-based resources, aligning with global sustainability goals.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy and good safety without adverse effects as known from conventional immunosuppressants.

NexMR is a Swiss company specializing in nuclear magnetic resonance (NMR) technology to enhance drug discovery processes. It provides key-in-hand solutions that optimize resource use and increase throughput within drug discovery pipelines. The company's platform accelerates screening processes by integrating machine learning for data analysis, enabling efficient exploration of uncharted target spaces. NexMR's proprietary NMR techniques allow for the rapid screening of extensive libraries of molecules, streamlining the evaluation of new compounds and improving the turnaround time for experimental results. Additionally, its technology serves quality control purposes, assisting researchers in determining the content, purity, and molecular structure of chemical samples, which aids healthcare professionals in assessing the viability of potential new drugs.

Biosimo Chemicals is a chemical engineering start-up focused on the development and operation of processes to produce bio-based platform chemicals. The company aims to create sustainable chemical solutions through innovative catalytic reactions and purification processes. Its flagship technology offers a novel method for producing acetic acid, replacing traditional methods that rely on coal and gas with a process that utilizes ethanol derived from biomass and waste. This advancement provides the chemical, pharmaceutical, and materials industries with a direct alternative to fossil-based resources, aligning with global sustainability goals.

NexMR is a Swiss company specializing in nuclear magnetic resonance (NMR) technology to enhance drug discovery processes. It provides key-in-hand solutions that optimize resource use and increase throughput within drug discovery pipelines. The company's platform accelerates screening processes by integrating machine learning for data analysis, enabling efficient exploration of uncharted target spaces. NexMR's proprietary NMR techniques allow for the rapid screening of extensive libraries of molecules, streamlining the evaluation of new compounds and improving the turnaround time for experimental results. Additionally, its technology serves quality control purposes, assisting researchers in determining the content, purity, and molecular structure of chemical samples, which aids healthcare professionals in assessing the viability of potential new drugs.

Adaptyv Bio is a biotechnology company focused on developing a protein engineering platform that leverages cell-free synthetic biology and high-throughput nanofluidics. The company's innovative technology aims to identify new antibodies for the treatment of various diseases by bridging the gap between computational predictions and experimental validation. Through its advanced methodologies, Adaptyv Bio seeks to enhance the efficacy of therapeutic interventions, ultimately improving patient outcomes.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at improving early detection of cachexia, a severe body-wasting syndrome often associated with cancer. The company's first-in-class CT contrast product is designed to identify signs of body wasting a year before noticeable weight loss occurs, allowing healthcare providers to detect cancer at an earlier stage. This advancement not only enhances the quality of life for patients but also increases their chances of survival against cancer and other chronic diseases. Through its pioneering imaging technology, Adiposs is positioned to make a significant impact in the field of oncology and patient care.

Nemosia is a company focused on the development of positron emission tomography (PET) tracers aimed at diagnosing neurological disorders. Utilizing advanced technology, Nemosia creates tracers that facilitate the early detection of neurodegenerative diseases by visualizing N-methyl-D-aspartate (NMDA) receptors in the brain. This innovative approach allows for timely intervention, enabling patients to take proactive measures against neurological conditions. Through its specialized PET imaging capabilities, Nemosia contributes to improved diagnostic accuracy and better patient outcomes in the field of neurology.

ArcoScreen is a Swiss medtech company focused on advancing drug discovery through its innovative microfluidic platform. This platform specializes in drug screening that targets cell membrane receptors, offering a faster and more efficient method for conducting chip-based GPCR assays. By enabling the identification of a drug's mode of action directly on patient cells, ArcoScreen's technology allows for the simultaneous testing of proteins that make up the drugs, assessing their efficacy in a single test. This approach aims to facilitate the treatment of complex diseases such as cancer, Alzheimer's, and diabetes, ultimately enhancing the drug development process for researchers.

Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.

Bionomous is a biotechnology company that specializes in the development of devices designed to automatically observe, analyze, and sort small biological entities. By integrating innovative micro-engineering design with advanced machine learning techniques, Bionomous's technology facilitates the automatic inspection and sorting of miniature biological entities. This capability is particularly beneficial for studies in genetics, development, behavioral biology, and toxicology, allowing biotech companies to automate critical processes such as visual inspection, sorting, and dispensing. Through its cutting-edge solutions, Bionomous aims to enhance efficiency and accuracy in biological research and applications.

peakPCR develops Polymerase Chain Reaction (PCR) devices for research and private laboratories. peakPCR is a low-cost, small size device capable of performing real-time polymerase chain reaction (qPCR). PCR is a method widely used in molecular biology to duplicate DNA segments, with applications such as genotyping, mutation detection, forensics, and paternity testing. The Polymerase Chain Reaction (PCR) is a widely used molecular technique to make millions of copies of a DNA sample, with applications in a variety of fields such as medical diagnostics, biotechnology, and forensic sciences. We have analyzed the heat transfer limitations of conventional PCR machines. This has led to the design of a completely new sample holder with extremely high heating and cooling rates and a much lower sample volume, in order to cut analysis time from currently 1-2 h down to 10 minutes, and reagent consumption by 90%. Next to a first stand-alone desktop instrument, we have also developed a portable version that is battery-powered and that operates in conjunction with a smartphone. We aim to deploy these PCR devices to research and private laboratories at affordable prices.

Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.

LifeMatrix is a biotechnology company focused on the development of biomimetic implants and bio-engineering technologies aimed at treating cardiovascular diseases and facilitating the growth of human replacement tissues. The company specializes in human cell-derived, off-the-shelf tissue-engineered implants that integrate with the patient's body post-implantation, allowing them to grow and regenerate. This innovative approach addresses the limitations of traditional implants, promoting faster recovery and improved outcomes for patients. LifeMatrix's technology is supported by over 20 years of research, resulting in more than 100 peer-reviewed publications and extensive preclinical studies demonstrating safety and efficacy, paving the way for clinical applications. The company's advancements are bolstered by various national and international research grants, reflecting its commitment to transforming the field of regenerative medicine.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at improving early detection of cachexia, a severe body-wasting syndrome often associated with cancer. The company's first-in-class CT contrast product is designed to identify signs of body wasting a year before noticeable weight loss occurs, allowing healthcare providers to detect cancer at an earlier stage. This advancement not only enhances the quality of life for patients but also increases their chances of survival against cancer and other chronic diseases. Through its pioneering imaging technology, Adiposs is positioned to make a significant impact in the field of oncology and patient care.

Bionomous is a biotechnology company that specializes in the development of devices designed to automatically observe, analyze, and sort small biological entities. By integrating innovative micro-engineering design with advanced machine learning techniques, Bionomous's technology facilitates the automatic inspection and sorting of miniature biological entities. This capability is particularly beneficial for studies in genetics, development, behavioral biology, and toxicology, allowing biotech companies to automate critical processes such as visual inspection, sorting, and dispensing. Through its cutting-edge solutions, Bionomous aims to enhance efficiency and accuracy in biological research and applications.

MimiX Biotherapeutics Sàrl is a Swiss company founded in 2016 that specializes in biofabrication technology focused on tissue manufacturing for therapeutic and diagnostic applications. Based in La Tène, the company aims to revolutionize regenerative and personalized medicine through its innovative point-of-care approach. By developing ultra-fast biomanufacturing technology, MimiX Biotherapeutics seeks to create patient-specific biological tissue equivalents, facilitating tailored treatments that meet individual medical needs.

Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at improving early detection of cachexia, a severe body-wasting syndrome often associated with cancer. The company's first-in-class CT contrast product is designed to identify signs of body wasting a year before noticeable weight loss occurs, allowing healthcare providers to detect cancer at an earlier stage. This advancement not only enhances the quality of life for patients but also increases their chances of survival against cancer and other chronic diseases. Through its pioneering imaging technology, Adiposs is positioned to make a significant impact in the field of oncology and patient care.

4i Labs generates multiplexed images of biological samples for molecular view of tumours.

Alibion AG is a therapeutics development company founded in 2018 and located in Allschwil, Switzerland. The company aims to bridge the gap between academic drug discoveries and patient access by accelerating the early-stage development of novel therapeutics. Recognizing that many promising therapies developed in academic settings often fail to progress to preclinical and clinical testing due to a lack of development partners, Alibion focuses on identifying and advancing these innovative compounds. By pooling necessary resources and managing drug development through outsourced partners, Alibion seeks to streamline processes, reduce costs, and ensure compliance with quality standards. Ultimately, the company is dedicated to improving patient outcomes globally by facilitating the transition of new therapies from labs to late-stage development.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at improving early detection of cachexia, a severe body-wasting syndrome often associated with cancer. The company's first-in-class CT contrast product is designed to identify signs of body wasting a year before noticeable weight loss occurs, allowing healthcare providers to detect cancer at an earlier stage. This advancement not only enhances the quality of life for patients but also increases their chances of survival against cancer and other chronic diseases. Through its pioneering imaging technology, Adiposs is positioned to make a significant impact in the field of oncology and patient care.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.

Mitoscreening platform (MSP) is used to screen metabolism-targeting anti-cancer drugs to discover.

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of innovative healthcare devices. The company has created EmbryoSpin, a device that performs microscopic Nuclear Magnetic Resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold. This groundbreaking device is designed to operate at the scale of a single human embryo, providing a robust and user-friendly solution for researchers. EmbryoSpin facilitates non-invasive embryo viability screening for in-vitro fertilization and enhances biochemical research by allowing detailed chemical analysis of microscopic samples. Annaida Technologies' advancements aim to improve outcomes in reproductive health and deepen understanding in various areas of biochemical research.

Viventis Microscopy develops an innovative light sheet microscope system designed for long-term live imaging of light-sensitive samples, such as embryos and organoids. The company provides both the hardware and custom microscope control software, facilitating advanced imaging capabilities for researchers and organizations. By enabling detailed observation of delicate biological structures, Viventis Microscopy supports efforts in drug development and other scientific endeavors, helping to accelerate research and enhance the understanding of complex biological processes.

Prolongate is a protein drugs and biotech company.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

BIOMEM

Nagi Bioscience SA is a Swiss company based in Lausanne that specializes in developing and manufacturing an innovative automated testing device utilizing organism-on-chip technology. This device leverages the microscopic worm Caenorhabditis elegans for in vivo testing, enabling pharmaceutical, chemical, and cosmetic companies to assess the toxic and beneficial effects of various substances. By integrating fully automated in vitro handling, culture, and analysis, Nagi Bioscience's platform facilitates toxicity testing, drug discovery, and anthelmintic testing. This approach allows clients to evaluate comprehensive biological responses that can only be observed at the level of the whole organism, thereby transforming traditional testing methodologies.

SEED Biosciences SA, founded in 2018 and based in Renens, Switzerland, is an award-winning startup specializing in innovative solutions for single-cell assays. The company develops DispenCell, a compact pipetting robot designed to enable scientists to precisely isolate single cells. This technology is crucial for various biological processes, including the production of biologics, cancer diagnosis, stem cell therapies, and personalized medicine.

Viventis Microscopy develops an innovative light sheet microscope system designed for long-term live imaging of light-sensitive samples, such as embryos and organoids. The company provides both the hardware and custom microscope control software, facilitating advanced imaging capabilities for researchers and organizations. By enabling detailed observation of delicate biological structures, Viventis Microscopy supports efforts in drug development and other scientific endeavors, helping to accelerate research and enhance the understanding of complex biological processes.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Clemedi AG is a Swiss-based company founded in 2018 that specializes in developing diagnostic workflows for infectious diseases. The company creates in vitro diagnostic tests by integrating next-generation sequencing and machine learning technologies. These innovative tests are designed to diagnose drug-resistant infections directly from patient samples within a single day, supporting timely and personalized antibiotic therapy. By providing healthcare professionals with critical information, Clemedi aims to enhance decision-making in the treatment of infectious diseases, ultimately contributing to the fight against antibiotic resistance. This approach is particularly significant given projections that antibiotic-resistant bacteria could lead to 10 million deaths annually by 2050.

Nagi Bioscience SA is a Swiss company based in Lausanne that specializes in developing and manufacturing an innovative automated testing device utilizing organism-on-chip technology. This device leverages the microscopic worm Caenorhabditis elegans for in vivo testing, enabling pharmaceutical, chemical, and cosmetic companies to assess the toxic and beneficial effects of various substances. By integrating fully automated in vitro handling, culture, and analysis, Nagi Bioscience's platform facilitates toxicity testing, drug discovery, and anthelmintic testing. This approach allows clients to evaluate comprehensive biological responses that can only be observed at the level of the whole organism, thereby transforming traditional testing methodologies.

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of innovative healthcare devices. The company has created EmbryoSpin, a device that performs microscopic Nuclear Magnetic Resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold. This groundbreaking device is designed to operate at the scale of a single human embryo, providing a robust and user-friendly solution for researchers. EmbryoSpin facilitates non-invasive embryo viability screening for in-vitro fertilization and enhances biochemical research by allowing detailed chemical analysis of microscopic samples. Annaida Technologies' advancements aim to improve outcomes in reproductive health and deepen understanding in various areas of biochemical research.

SEED Biosciences SA, founded in 2018 and based in Renens, Switzerland, is an award-winning startup specializing in innovative solutions for single-cell assays. The company develops DispenCell, a compact pipetting robot designed to enable scientists to precisely isolate single cells. This technology is crucial for various biological processes, including the production of biologics, cancer diagnosis, stem cell therapies, and personalized medicine.

Viventis Microscopy develops an innovative light sheet microscope system designed for long-term live imaging of light-sensitive samples, such as embryos and organoids. The company provides both the hardware and custom microscope control software, facilitating advanced imaging capabilities for researchers and organizations. By enabling detailed observation of delicate biological structures, Viventis Microscopy supports efforts in drug development and other scientific endeavors, helping to accelerate research and enhance the understanding of complex biological processes.

Nagi Bioscience SA is a Swiss company based in Lausanne that specializes in developing and manufacturing an innovative automated testing device utilizing organism-on-chip technology. This device leverages the microscopic worm Caenorhabditis elegans for in vivo testing, enabling pharmaceutical, chemical, and cosmetic companies to assess the toxic and beneficial effects of various substances. By integrating fully automated in vitro handling, culture, and analysis, Nagi Bioscience's platform facilitates toxicity testing, drug discovery, and anthelmintic testing. This approach allows clients to evaluate comprehensive biological responses that can only be observed at the level of the whole organism, thereby transforming traditional testing methodologies.

Lipidon is a bioanalytical service company that specializes in lipid research and lipidomics analytical services. The company focuses on identifying and developing novel biomarkers tailored for the life sciences, cosmetic, and food industries. By providing actionable biomarker discovery, Lipidon aids in precision medicine and various sectors, including pharmaceuticals, biotechnology, cosmetics, and food. The company’s services enable clients to distinguish between products of animal and herbal origin, facilitating informed decision-making in their respective fields.

Clemedi AG is a Swiss-based company founded in 2018 that specializes in developing diagnostic workflows for infectious diseases. The company creates in vitro diagnostic tests by integrating next-generation sequencing and machine learning technologies. These innovative tests are designed to diagnose drug-resistant infections directly from patient samples within a single day, supporting timely and personalized antibiotic therapy. By providing healthcare professionals with critical information, Clemedi aims to enhance decision-making in the treatment of infectious diseases, ultimately contributing to the fight against antibiotic resistance. This approach is particularly significant given projections that antibiotic-resistant bacteria could lead to 10 million deaths annually by 2050.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

SEED Biosciences SA, founded in 2018 and based in Renens, Switzerland, is an award-winning startup specializing in innovative solutions for single-cell assays. The company develops DispenCell, a compact pipetting robot designed to enable scientists to precisely isolate single cells. This technology is crucial for various biological processes, including the production of biologics, cancer diagnosis, stem cell therapies, and personalized medicine.

UniteLabs, AG is a software company based in Basel, Switzerland, established in 2017, specializing in automation solutions for life science research facilities. The company develops an infrastructure platform that integrates hardware and software across various vendors, facilitating the digitalization of life science research and development. UniteLabs offers plug-and-play robotic lab assistants and control software solutions that enable users to automate laboratory equipment, enhancing the quality and reproducibility of scientific experiments. Its platform supports seamless integration and allows for the rapid construction and deployment of custom workflows, promoting a sustainable and flexible laboratory architecture. By providing access to a growing library of connectors and software development kits for API control, UniteLabs transforms laboratory operations and accelerates scientific throughput.

Dicronis GmbH, founded in 2018 and based in Monteggio, Switzerland, specializes in the development of innovative microneedle technology for diagnostic and therapeutic applications. The company's flagship product, Lymphit, is a wearable device designed to monitor lymphatic function in a safe and scalable manner from the patient's home. This device allows for the early diagnosis of secondary lymphedema, a significant complication that can arise from cancer treatments. By utilizing a wearable patch that applies a fluorescent substance to the skin, Lymphit measures its uptake into lymph vessels through a portable detector. This real-time monitoring enables healthcare providers to diagnose lymphedema before symptoms develop and to tailor conservative treatment strategies effectively. As a result, Dicronis aims to improve patient outcomes and quality of life while also generating cost savings for the healthcare system.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Gnubiotics Sciences SA is a biotechnology company based in Epalinges, Switzerland, focused on developing microbiome-modulating products for both humans and animals. Founded in 2016, the company specializes in producing glycans that enhance microbiome diversity and promote gut health. One of its notable products, AMObiomeTM, serves as a natural ingredient aimed at improving microbiome balance and overall wellness. Gnubiotics is also engaged in creating functional and structural mimics of Human Milk Oligosaccharides, which are designed to replicate the beneficial properties of breast milk. These innovations are intended to prevent infections, combat diet-induced obesity, and support immune health by nurturing a diverse microbiome.

Certus Molecular Diagnostics AG specializes in the development and provision of molecular rapid tests designed for the on-site detection of mycoplasma contamination in cell cultures, as well as the identification of specific genes in various microorganisms. Founded in 2007 and headquartered in Bern, Switzerland, the company aims to enhance the reliability and efficiency of microbial testing in laboratory settings. By focusing on rapid diagnostics, Certus Molecular Diagnostics addresses critical needs in research and clinical environments, offering solutions that facilitate timely decision-making and quality control in cell culture processes. The company serves both domestic and international markets, contributing to advancements in molecular diagnostics.

Dicronis GmbH, founded in 2018 and based in Monteggio, Switzerland, specializes in the development of innovative microneedle technology for diagnostic and therapeutic applications. The company's flagship product, Lymphit, is a wearable device designed to monitor lymphatic function in a safe and scalable manner from the patient's home. This device allows for the early diagnosis of secondary lymphedema, a significant complication that can arise from cancer treatments. By utilizing a wearable patch that applies a fluorescent substance to the skin, Lymphit measures its uptake into lymph vessels through a portable detector. This real-time monitoring enables healthcare providers to diagnose lymphedema before symptoms develop and to tailor conservative treatment strategies effectively. As a result, Dicronis aims to improve patient outcomes and quality of life while also generating cost savings for the healthcare system.

MesenFlow Technologies specializes in innovative bio-imaging technology aimed at enhancing drug and cosmetic development. The company’s platform addresses critical challenges in modern drug development, including species cross-reactivity and the ethical concerns of animal testing. By utilizing proprietary protocols on primary human cells, MesenFlow enables early definition of a drug's mechanism of action and its relevance to human biology. This approach not only accelerates the pharmaceutical testing process but also extends to the cosmetics and nutraceutical sectors, allowing for the assessment of product safety and efficacy at an early stage. MesenFlow's technology is particularly beneficial for organizations requiring animal-free testing solutions, ensuring compliance with regulatory demands while prioritizing human biological impact.

Haelixa LLC, founded in 2012 and based in Zürich, Switzerland, specializes in DNA-based tracing and tagging technology aimed at enhancing supply chain transparency and integrity. The company develops innovative tracing solutions for various sectors, including the energy industry, where it offers water and oil tracers to monitor the movement of fluids in subsurface environments, as well as groundwater tracing solutions. Beyond the energy sector, Haelixa provides product identification solutions that help prevent counterfeiting and other irregularities, thereby reinforcing supply chain sustainability. Its proprietary platform enables clients to physically mark, trace, and authenticate products from production to retail, ensuring brand protection and proof of authenticity for a wide range of goods, including textiles and precious materials.

Gnubiotics Sciences SA is a biotechnology company based in Epalinges, Switzerland, focused on developing microbiome-modulating products for both humans and animals. Founded in 2016, the company specializes in producing glycans that enhance microbiome diversity and promote gut health. One of its notable products, AMObiomeTM, serves as a natural ingredient aimed at improving microbiome balance and overall wellness. Gnubiotics is also engaged in creating functional and structural mimics of Human Milk Oligosaccharides, which are designed to replicate the beneficial properties of breast milk. These innovations are intended to prevent infections, combat diet-induced obesity, and support immune health by nurturing a diverse microbiome.

Haelixa LLC, founded in 2012 and based in Zürich, Switzerland, specializes in DNA-based tracing and tagging technology aimed at enhancing supply chain transparency and integrity. The company develops innovative tracing solutions for various sectors, including the energy industry, where it offers water and oil tracers to monitor the movement of fluids in subsurface environments, as well as groundwater tracing solutions. Beyond the energy sector, Haelixa provides product identification solutions that help prevent counterfeiting and other irregularities, thereby reinforcing supply chain sustainability. Its proprietary platform enables clients to physically mark, trace, and authenticate products from production to retail, ensuring brand protection and proof of authenticity for a wide range of goods, including textiles and precious materials.

Dicronis GmbH, founded in 2018 and based in Monteggio, Switzerland, specializes in the development of innovative microneedle technology for diagnostic and therapeutic applications. The company's flagship product, Lymphit, is a wearable device designed to monitor lymphatic function in a safe and scalable manner from the patient's home. This device allows for the early diagnosis of secondary lymphedema, a significant complication that can arise from cancer treatments. By utilizing a wearable patch that applies a fluorescent substance to the skin, Lymphit measures its uptake into lymph vessels through a portable detector. This real-time monitoring enables healthcare providers to diagnose lymphedema before symptoms develop and to tailor conservative treatment strategies effectively. As a result, Dicronis aims to improve patient outcomes and quality of life while also generating cost savings for the healthcare system.

Cellphmed is a biotechnology company focused on advancing genomic research through its innovative tools that explore uncharted regions of the genome. The company specializes in developing human cell barcodes that utilize next-generation RNA sequencing technology, allowing for the verification of human cell identity and quality. By deciphering millions of previously unexplored RNA biomarkers, Cellphmed enables biomedical researchers to access vast amounts of genomic information. This capability supports critical areas such as virology, oncology, drug discovery, and diagnostics, facilitating enhanced human cell qualification and the development of new therapeutic strategies.

Embion Technologies SA, founded in 2016 and based in Ecublens, Switzerland, specializes in the extraction of prebiotic ingredients from industrial plant byproduct feedstocks for both human and animal nutrition. The company focuses on developing and marketing advanced bioactive nutritional ingredients that support sugar reduction and microbiome health. By employing innovative biomass processing technology, Embion aims to produce natural, sustainable products with low emissions and high functionality, addressing the growing global demand for nutrition and promoting a circular bioeconomy. Their unique approach not only enhances the efficiency of product development but also significantly reduces costs and time-to-market for clients in the nutrition sector.

Synple Chem AG, based in Zurich, Switzerland, specializes in the development of automated reagent cartridge-based synthesizers designed to enhance the efficiency of chemical synthesis in laboratories, particularly in drug discovery. Founded in 2016, the company offers products such as Synple 1 and Synple 2, which utilize revolutionary reagent capsules to enable faster and more efficient synthesis of organic compounds. This innovative technology allows researchers, even those with limited chemistry expertise, to conduct complex reactions in a fully automated manner, simplifying the process by minimizing the need for precise measurements and reducing reagent waste. By streamlining the synthesis process, Synple Chem aims to significantly accelerate drug discovery cycles, helping researchers advance their projects more quickly than traditional methods permit.

Haelixa LLC, founded in 2012 and based in Zürich, Switzerland, specializes in DNA-based tracing and tagging technology aimed at enhancing supply chain transparency and integrity. The company develops innovative tracing solutions for various sectors, including the energy industry, where it offers water and oil tracers to monitor the movement of fluids in subsurface environments, as well as groundwater tracing solutions. Beyond the energy sector, Haelixa provides product identification solutions that help prevent counterfeiting and other irregularities, thereby reinforcing supply chain sustainability. Its proprietary platform enables clients to physically mark, trace, and authenticate products from production to retail, ensuring brand protection and proof of authenticity for a wide range of goods, including textiles and precious materials.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing microbiome therapies for gastrointestinal diseases. Established in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create treatments for conditions that disrupt the gut microbiota ecosystem, including clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome utilizes an innovative technology platform that facilitates the efficient development and production of defined, function-based microbiome therapies, enabling swift translation from research to clinical product readiness. The company's proprietary pipeline emphasizes the use of tailored, ecologically sound bacterial mixtures, distinguishing its approach from traditional fecal microbiota transplantation methods, thus offering a new standard for treating intestinal infections.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing microbiome therapies for gastrointestinal diseases. Established in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create treatments for conditions that disrupt the gut microbiota ecosystem, including clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome utilizes an innovative technology platform that facilitates the efficient development and production of defined, function-based microbiome therapies, enabling swift translation from research to clinical product readiness. The company's proprietary pipeline emphasizes the use of tailored, ecologically sound bacterial mixtures, distinguishing its approach from traditional fecal microbiota transplantation methods, thus offering a new standard for treating intestinal infections.

Selmod, located in Basel, Switzerland, specializes in the development of innovative small molecule therapies aimed at treating life-threatening, multi-drug resistant infections. The company is committed to discovering and advancing first-in-class drug candidates that provide second-line and last-resort treatment options for patients in hospital settings, particularly where conventional therapies have failed due to resistance. Selmod's approach includes the development of antibiotics with dual modes of action to effectively counteract existing resistance mechanisms. Its leading candidates, SLM500, SLM100, and SLM300, have demonstrated success in preclinical animal studies and are positioned within a promising market projected to exceed $9 billion. The company aims to capture a substantial market share shortly after entry, supported by a leadership team with extensive experience in clinical development for major pharmaceutical firms. Funding will be utilized to advance SLM500 through IND-enabling studies and to optimize additional lead candidates for further development.

ImmuProbe develops a protein quantification system, which is characterized by both an outstanding performance at very small sample volumes as well as low acquisition and consumable costs. We designed an approach to outmatching state-of-the-art technology in terms of usability, speed, and customisability: the BoxProbe. With this system, we intend to overcome the current limitations in research studies relying on small laboratory animals, resulting in improved quality of obtained data and drastically decreasing the number of animals needed, allowing scientists to efficiently apply the principles of the three Rs (replace, refine, reduce) of animal welfare. In the long-term future, we will apply our technology to improve the present practice in infant diagnostics.

SiMPLInext SA is a biotechnology company founded in 2016 and headquartered in Biel/Bienne, Switzerland. The company specializes in the development of cell-based assays, protocols, and in-vitro substances that enhance biological research. Its technologies enable biologists to investigate the permeability of biological membranes to nanoparticles, and also extend permeability studies to non-cellular membranes like mucuses and biofilms. By facilitating the observation of cellular cross-transport, SiMPLInext aims to advance in-vitro research through innovative and ergonomic solutions.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing microbiome therapies for gastrointestinal diseases. Established in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create treatments for conditions that disrupt the gut microbiota ecosystem, including clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome utilizes an innovative technology platform that facilitates the efficient development and production of defined, function-based microbiome therapies, enabling swift translation from research to clinical product readiness. The company's proprietary pipeline emphasizes the use of tailored, ecologically sound bacterial mixtures, distinguishing its approach from traditional fecal microbiota transplantation methods, thus offering a new standard for treating intestinal infections.

TwentyGreen is a Swiss company that specializes in the production of probiotic feed supplements aimed at enhancing sustainable animal farming practices. Founded in 2015 and based in Root, Switzerland, the company has developed a unique triple active probiotic product that addresses challenges faced in intensive animal farming, such as improving digestion, enhancing feed conversion ratios, and reducing disease and pollution. The probiotic supplement is grounded in research from the École Polytechnique Fédérale de Lausanne, focusing on the enhancement of gut microbiota, which is crucial for food metabolism and immune defense. Targeting animal farmers, feed suppliers, and large retailers, TwentyGreen aims to capture a 10% share of the rapidly growing global animal feed probiotic market, which exceeds $4 billion annually. The commercialization of their product involves rigorous research and development in collaboration with esteemed academic partners to meet regulatory standards for animal feed.

NeuroCycle Therapeutics, founded in 2018 and based in Cambridge, Massachusetts, is a biopharmaceutical company specializing in the development of small molecule drugs that target the nervous system. The company's primary focus is on sub-type selective GABA-A modulation, aiming to deliver next-generation treatments for chronic itch, pain, and certain refractory forms of pediatric epilepsy. Their lead candidate, NCT10004, has demonstrated significant efficacy across various models without causing sedation, immune suppression, dependency/addiction issues, or losing effectiveness over time.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

SiMPLInext SA is a biotechnology company founded in 2016 and headquartered in Biel/Bienne, Switzerland. The company specializes in the development of cell-based assays, protocols, and in-vitro substances that enhance biological research. Its technologies enable biologists to investigate the permeability of biological membranes to nanoparticles, and also extend permeability studies to non-cellular membranes like mucuses and biofilms. By facilitating the observation of cellular cross-transport, SiMPLInext aims to advance in-vitro research through innovative and ergonomic solutions.

SimplicityBio SA is a biotechnology company based in Monthey, Switzerland, founded in 2013 by Matthew Hall, Pedro Faustino, and Miguel Barreto. The company specializes in developing an artificial intelligence-based platform designed to analyze biological, clinical, and digital data streams, facilitating the extraction of knowledge and insights that expedite the development of biomarker signatures throughout various stages, from target identification to pre-clinical and clinical phases. Its services encompass biomarker discovery and ranking, signature creation, and the enhancement of existing signatures, catering to the molecular diagnostic market. In addition to its analytical capabilities, SimplicityBio also focuses on developing scientific innovations, intellectual property, and white paper technologies for its clients. As of March 2019, SimplicityBio operates as a subsidiary of Precision for Medicine, Inc.

Spectroswiss Sarl is a Swiss company established in 2014 and based in Lausanne, specializing in biological mass spectrometry. It develops advanced mass analyzers and data acquisition electronics designed to enhance research in life sciences and biotechnology. The company employs proprietary methods for processing time-domain data, enabling super-resolution signal processing in Fourier transform mass spectrometry (FTMS). This innovative approach allows clients to conduct both qualitative and quantitative analyses of proteins and metabolites, facilitating vital research and applications in the life sciences sector. Spectroswiss aims to accelerate scientific discovery by providing sophisticated tools for proteomics and metabolomics analysis.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.

SimplicityBio SA is a biotechnology company based in Monthey, Switzerland, founded in 2013 by Matthew Hall, Pedro Faustino, and Miguel Barreto. The company specializes in developing an artificial intelligence-based platform designed to analyze biological, clinical, and digital data streams, facilitating the extraction of knowledge and insights that expedite the development of biomarker signatures throughout various stages, from target identification to pre-clinical and clinical phases. Its services encompass biomarker discovery and ranking, signature creation, and the enhancement of existing signatures, catering to the molecular diagnostic market. In addition to its analytical capabilities, SimplicityBio also focuses on developing scientific innovations, intellectual property, and white paper technologies for its clients. As of March 2019, SimplicityBio operates as a subsidiary of Precision for Medicine, Inc.

Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.

AlveoliX AG is a Swiss company based in Bern that specializes in drug development by providing innovative in-vitro solutions through its proprietary organ-on-chip technologies. These advanced in-vitro models are designed to closely replicate the human lung environment, significantly enhancing the predictive accuracy of drug responses compared to traditional in-vitro and in-vivo models. By improving preclinical decision-making, AlveoliX aims to streamline the drug discovery process, reduce development costs, and minimize the reliance on animal testing. Its products facilitate a safer and more personalized approach to drug discovery, ultimately helping to identify viable drug candidates more efficiently before clinical trials.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.

Ectica Technologies AG is a Zurich-based company that specializes in the development and manufacturing of hydrogel-based tools tailored for the biopharmaceutical and life sciences sectors. Founded in 2015, the company focuses on advancing 3D cell culture technologies to enhance drug discovery and bioresearch. Its flagship product, the 3D ProSeed Hydrogel well-plate, allows for high biological relevance in cell culture, closely mimicking the natural conditions found in the human body. This innovative technology facilitates automation-compatible cell-based assays, supporting pharmaceutical companies, contract research organizations, and academic laboratories in their preclinical drug discovery efforts. Additionally, Ectica Technologies offers services in assay development, technology integration, and custom production, catering especially to startup companies within the industry.

AlveoliX AG is a Swiss company based in Bern that specializes in drug development by providing innovative in-vitro solutions through its proprietary organ-on-chip technologies. These advanced in-vitro models are designed to closely replicate the human lung environment, significantly enhancing the predictive accuracy of drug responses compared to traditional in-vitro and in-vivo models. By improving preclinical decision-making, AlveoliX aims to streamline the drug discovery process, reduce development costs, and minimize the reliance on animal testing. Its products facilitate a safer and more personalized approach to drug discovery, ultimately helping to identify viable drug candidates more efficiently before clinical trials.

Nanolive SA is a Swiss company that specializes in the design and development of advanced imaging devices for live cells. Established in 2013 and headquartered in Ecublens, Switzerland, the company offers the 3D Cell Explorer, a cutting-edge technology that allows researchers to visualize the interior of living cells in three dimensions without the need for labeling or invasive techniques. This innovative device enables detailed observation of various cellular processes such as cell division, organelle structure, cell morphology, differentiation, and interactions between cells. By capturing unbiased live cell data, Nanolive's technology supports the research and development of new drugs and therapies, facilitating quality analysis and providing valuable biological insights for scientists and researchers in the field of life sciences.